ZURICH (Reuters) – Roche said on Wednesday it plans to complete the purchase of U.S. biopharmaceutical company Poseida Therapeutics through its subsidiary Blue Giant Acquisition Corp.
Roche said it had accepted payment for nearly 65 million shares in Poseida – equivalent to 66% of the California company’s shares – which shareholders had offered at a price of $9 per share, with an additional contingent payment of up to $4 per share.
